Novo Nordisk’s ziltivekimab posted negative results in the ZEUS trial, presented at the AHA 2026 conference. Cardiologists told STAT that the miss does not undercut the view that inflammation matters in cardiovascular disease and that they will keep working on anti-inflammatory approaches.